Health‐related quality of life (HRQL) · adults and children with exercise‐induced bronchoconstriction/asthma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Asthma exacerbations · adults and children with exercise‐induced bronchoconstriction/asthma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Lung function: FEV1 % drop Postexercise · adults and children with exercise‐induced bronchoconstriction/asthma
1 finding from 1 review
no estimate extracted
1 study · 8 participants
Low
Asthma symptoms · adults and children with exercise‐induced bronchoconstriction/asthma
1 finding from 1 review
no estimate extracted
1 study · 8 participants
Low
Progression to late AMD (neovascular AMD, geographic atrophy or both) · people with AMD
Antioxidant multivitamin and mineral supplement probably leads to lower progression to late AMD (neovascular AMD, geographic atrophy, or both) compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Progression to neovascular AMD · people with AMD
Antioxidant multivitamin and mineral supplement probably leads to lower progression to neovascular AMD compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Progression to geographic atrophy · people with AMD
Antioxidant multivitamin and mineral supplement showed no clear difference in progression to geographic atrophy compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Progression to visual loss (loss of 3 or more lines on logMAR chart) · people with AMD
Antioxidant multivitamin and mineral supplement probably leads to lower progression to visual loss (loss of 3 or more lines on logMAR chart) compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Quality of life · people with AMD
1 finding from 1 review
Adverse effects · people with AMD
Antioxidant multivitamin and mineral supplement may leads to lower adverse effects compared with placebo or no treatment (low certainty).
1 finding from 1 review
Resource use and costs · people with AMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of acute URTIs during the study period (the number of acute URTIs over a period of time) · children up to the age of 7 at risk of upper respiratory tract infection
Summary of findings table ‐ Vitamin A supplements showed no clear difference in incidence of acute URTIs during the study period (the number of… compared with placebo (low certainty).
1 finding from 1 review
Incidence of acute URTIs during the study period (proportion of participants with an acute URTI) · children up to the age of 7 at risk of upper respiratory tract infection
1 finding from 1 review
Adverse events · children up to the age of 7 at risk of upper respiratory tract infection
1 finding from 1 review
Severity of subjective symptoms (mean duration of acute URTI) · children up to the age of 7 at risk of upper respiratory tract infection
1 finding from 1 review
Time to occurrence of acute URTI ‐ not reported · children up to the age of 7 at risk of upper respiratory tract infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of cases with complications ‐ not reported · children up to the age of 7 at risk of upper respiratory tract infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Rate of hospitalisation ‐ not reported · children up to the age of 7 at risk of upper respiratory tract infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Maternal death · women in the postpartum period
Vitamin A supplementation (200,000 to 400,000 IU) showed no clear difference in maternal mortality compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Maternal morbidity (diarrhoea, respiratory infections, fever) · women in the postpartum period
1 finding from 1 review